



# iShares Healthcare Innovation UCITS ETF U.S. Dollar (Accumulating) iShares IV plc



May 2024

Unless otherwise stated, Performance, Portfolio Breakdowns and Net Assets information as at: 31-May-2024. All other data as at 08-Jun-2024.

For Qualified Investors and Qualified Clients only.

### **FUND OVERVIEW**

The Fund seeks to track the performance of an index composed of developed and emerging market companies which are generating significant revenues from specific sectors focused on pushing the boundaries in medical treatment and technology

#### **KEY BENEFITS**

- 1. Competitively priced and diversified access to companies across the world that are focused on innovation within global healthcare services, across both developed and emerging markets.
- 2. Growth potential due to major structural drivers including shifting global demographics, social changes and the increased application of technology.
- 3. Express a long-term view within your equity allocation through an ETF tracking an ESG-screened index (screened for Controversial Weapons, Weapons, Tobacco, Nuclear Power, Thermal Coal, Oil & Gas, and companies involved in severe ESG controversies).

## **RISK INDICATOR**

### **Lower Risk**

Potentially Lower Rewards

Higher Risk

Potentially Higher Rewards



**CAPITAL AT RISK:** The value of investments and the income from them can fall as well as rise and are not guaranteed. Investors may not get back the amount originally invested.

#### **KEY RISKS:**

- Shares in smaller companies typically trade in less volume and experience greater price variations than larger companies.
- Emerging markets are generally more sensitive to economic and political conditions than developed markets. Other factors include greater 'Liquidity Risk', restrictions on investment or transfer of assets, failed/delayed delivery of securities or payments to the Fund and sustainability-related risks.
- Investment risk is concentrated in specific sectors, countries, currencies or companies. This means the Fund is more sensitive to any localised economic, market, political, sustainability-related or regulatory events.
- The value of equities and equity-related securities can be affected by daily stock market movements. Other influential factors include political, economic news, company earnings and significant corporate events.
- Counterparty Risk: The insolvency of any institutions providing services such as safekeeping of assets or acting as counterparty to derivatives or other instruments, may expose the Share Class to financial loss.
- Liquidity Risk: Lower liquidity means there are insufficient buyers or sellers to allow the Fund to sell or buy investments readily.

# PRODUCT INFORMATION ISIN : IE00BYZK4776 Share Class Launch Date : 08-Sep-2016

Share Class Currency : USD

Total Expense Ratio: 0.40%

Use of Income : Accumulating

Net Assets of Share Class (M): 1,040.29 USD

#### **KEY FACTS**

Asset Class : Equity

**Benchmark :** STOXX Global Breakthrough Healthcare Index

Fund Launch Date: 08-Sep-2016

Net Assets of Fund (M): 1,040.29 USD

SFDR Classification : Article 8

#### Domicile : Ireland

Methodology: Optimised

Issuing Company : iShares IV plc

Product Structure : Physical

# **PORTFOLIO CHARACTERISTICS**

Price to Book Ratio : 3.63x Price to Earnings Ratio : 32.93x


**3y Beta :** 1.00


Number of Holdings: 196

# iShares Healthcare Innovation UCITS ETF **U.S. Dollar (Accumulating)**



**iShares IV plc** 





CUMULATIVE & ANNUALISED PERFORMANCE										
		C	UMULATIVE (%	ANNUALISED (% p.a.)						
	1m	3m	6m	YTD	ly	Зу	5у	Since Inception		
Share Class	2.28	-2.36	9.22	-1.08	0.09	-9.83	4.25	5.10		
Benchmark	2.31	-2.44	9.19	-1.10	0.11	-9.63	4.45	5.31		

The figures shown relate to past performance. Past performance is not a reliable indicator of current or future performance and should not be the sole factor of consideration when selecting a product or strategy. Share Class and Benchmark performance displayed in USD, hedged share class benchmark performance is displayed in USD. Performance is shown on a Net Asset Value (NAV) basis, with gross income reinvested where applicable. The return of your investment may increase or decrease as a result of currency fluctuations if your investment is made in a currency other than that used in the past performance calculation. Source: BlackRock


Share Class iShares Healthcare Innovation UCITS ETF U.S. Dollar (Accumulating)

Benchmark STOXX Global Breakthrough Healthcare Index

# iShares Healthcare Innovation UCITS ETF U.S. Dollar (Accumulating) iShares IV plc



TOP 10 HOLDINGS (%)	
UCB SA	2.13%
BOSTON SCIENTIFIC CORP	2.09%
NATERA INC	2.06%
NEUROCRINE BIOSCIENCES INC	2.03%
AMGEN INC	1.95%
GLAXOSMITHKLINE	1.84%
INTUITIVE SURGICAL INC	1.82%
MEDPACE HOLDINGS INC	1.75%
CATALENT INC	1.72%
ABBVIE INC	1.65%
Total of Portfolio	19.04%
Holdings are subject to change.	




# TRADING INFORMATION

I RADING INFORMATION								
Exchange	SIX Swiss Exchange	London Stock Exchange	Euronext Amsterdam					
Ticker	HEAL	HEAL	HEAL					
Bloomberg Ticker	HEAL SW	HEAL LN	-					
RIC	HEAL.S	HEAL.L	DRDR.AS					
SEDOL	BD41ZS2	BYZK477	BP2P7C8					
VALOR	33305547	33305547	33305547					
Listing Currency	USD	USD	EUR					
This product is also listed on: Xetra,Tel Aviv Stock Exchange,Bolsa Mexicana De Valores,Santiago Stock Exchange,Borsa Italiana								

#### **GEOGRAPHIC BREAKDOWN (%)** 69.86 United States 5.09 Switzerland 4.80 Japan Korea (South) 3.80 3.66 Belgium 2.70 Germany 2.54 Denmark 2.00 United Kingdom 1.87 France 1.46 Sweden 15 30 45 60 75 Ō Fund 📃

Geographic exposure relates principally to the domicile of the issuers of the securities held in the product, added together and then expressed as a percentage of the product's total holdings. However, in some instances it can reflect the location where the issuer of the securities carries out much of their business.



#### Contact Us For EMEA: +353 1 612 3394 • www.blackrock.com • investor.services@blackrock.com

# iShares Healthcare Innovation UCITS ETF U.S. Dollar (Accumulating) iShares IV plc



### GLOSSARY

**SFDR Classification: Article 8:** Products that promote environmental or social characteristics and promote good governance practices. **Article 9:** Products that have sustainable investments as an objective and follow good governance practices. **Other:** Products that do not meet the criteria to be classified as Article 8 or 9.

**Price to Earnings:** A valuation ratio of a company's current share price compared to its per-share earnings in the current forecast year, calculated as current share price divided by current earnings per share.

**Price to Book Ratio:** represents the ratio of the current closing price of the share to the latest quarter's book value per share.

#### **IMPORTANT INFORMATION:**

This material is for distribution to Professional Clients (as defined by the Financial Conduct Authority or MiFID Rules) only and should not be relied upon by any other persons.

In the UK and Non-European Economic Area (EEA) countries: This is issued by BlackRock Advisors (UK) Limited, which is authorised and regulated by the Financial Conduct Authority. Registered office: 12 Throgmorton Avenue, London, EC2N 2DL, Tel: +44 (0)20 7743 3000. Registered in England and Wales No. 00796793. For your protection, calls are usually recorded. Please refer to the Financial Conduct Authority website for a list of authorised activities conducted by BlackRock.

iShares plc, iShares II plc, iShares III plc, iShares IV plc, iShares V plc, iShares VI plc and iShares VII plc (together 'the Companies') are open-ended investment companies with variable capital having segregated liability between their funds organised under the laws of Ireland and authorised by the Central Bank of Ireland.

Further information about the Fund and the Share Class, such as details of the key underlying investments of the Share Class and share prices, is available on the iShares website at www.ishares.com or by calling +44 (0)845 357 7000 or from your broker or financial adviser. The indicative intra-day net asset value of the Share Class is available at http://deutsche-boerse.com and/or http://www.reuters.com. A UCITS ETF's units / shares that have been acquired on the secondary market cannot usually be sold directly back to the UCITS ETF itself. Investors who are not Authorised Participants must buy and sell shares on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees and additional taxes in doing so. In addition, as the market price at which the Shares are traded on the secondary market may differ from the Net Asset Value per Share, investors may pay more than the then current Net Asset Value per Share when buying shares and may receive less than the current Net Asset Value per Share when selling them.

**For investors in Switzerland:** For professional clients and qualified investors only. This document is marketing material. This document shall be exclusively made available to, and directed at, qualified investors as defined in Article 10 (3) of the CISA of 23 June 2006, as amended, at the exclusion of qualified investors with an opting-out pursuant to Art. 5 (1) of the Swiss Federal Act on Financial Services ("FinSA"). For information on art. 8 / 9 Financial Services Act (FinSA) and on your client segmentation under art. 4 FinSA, please see the following website: www.blackrock.com/ finsa.

The iShares ETFs are domiciled in Ireland, Switzerland and Germany. BlackRock Asset Management Schweiz AG, Bahnhofstrasse 39, CH-8001 Zurich, is the Swiss Representative and State Street International GmbH, Munich, Zurich Branch, Beethovenstrasse 19, CH-8002 Zürich the Swiss Paying Agent for the foreign iShares ETFs registered in Switzerland. The Prospectus, the Prospectus with integrated fund contract, the Packaged Retail and Insurance-based Investment Products Key Information Document (PRIIPs KID) or equivalent, the general and particular conditions, the Articles of Incorporation, the latest and any previous annual and semi-annual reports of the iShares ETFs domiciled or registered in Switzerland are available free of charge from BlackRock Asset Management Schweiz AG. Investors should read the fund specific risks in the PRIIPs KID and the Prospectus.

**Capital at risk:** Past performance is not a reliable indicator of current or future results and should not be the sole factor of consideration when selecting a product or strategy. Changes in the rates of exchange between currencies may cause the value of investments to diminish or increase. Fluctuation may be particularly marked in the case of a higher volatility fund and the value of an investment may fall suddenly and substantially. Levels and basis of taxation may change from time to time and depend on personal individual circumstances. BlackRock has not considered the suitability of this investment against your individual needs and risk tolerance. The data displayed provides summary information. Investment should be made on the basis of the relevant Prospectus which is available from the manager. The products mentioned in this document are intended for information purposes only and do not constitute investment advice or an offer to sell or a solicitation of an offer to buy the securities described within. This document may not be distributed without authorisation from BlackRock.

**Restricted Investors:** This document is not, and under no circumstances is to be construed as an advertisement or any other step in furtherance of a public offering of shares in the United States or Canada. This document is not aimed at persons who are resident in the United States, Canada or any province or territory thereof, where the companies/securities are not authorised or registered for distribution and where no prospectus has been filed with any securities commission or regulatory authority. The companies/securities may not be acquired or owned by, or acquired with the assets of, an ERISA Plan.

Bloomberg MSCI December 2025 Maturity USD Corporate ESG Screened Index is the intellectual property (including registered trademarks) of STOXX Limited, Zurich, Switzerland ("STOXX"), Deutsche Börse Group or their licensors, which is used under license. The iShares ETF is neither sponsored nor promoted, distributed or in any other manner supported by STOXX, Deutsche Börse Group or their licensors, research partners or data providers and STOXX, Deutsche Börse Group and their licensors, research partners or data providers do not give any warranty, and exclude any liability (whether in negligence or otherwise) with respect thereto generally or specifically in relation to any errors, omissions or interruptions in the relevant index or its data.

Any research in this document has been procured and may have been acted on by BlackRock for its own purpose. The results of such research are being made available only incidentally. The views expressed do not constitute investment or any other advice and are subject to change. They do not necessarily reflect the views of any company in the BlackRock Group or any part thereof and no assurances are made as to their accuracy.

© 2024 BlackRock, Inc. All Rights reserved. BLACKROCK, BLACKROCK SOLUTIONS and iSHARES are trademarks of BlackRock, Inc. or its subsidiaries in the United States and elsewhere. All other trademarks are those of their respective owners.